Patent cliffs & loss of exclusivity
Deciphera Pharmaceuticals is a biotechnology company founded in 2003 by Daniel Flynn. It develops medicines for cancer and other serious diseases, with research programs in oncology, neurology, immunology and inflammation. Its marketed medicines include QINLOCK and ROMVIMZA. Headquartered in Waltham, Massachusetts, it became a subsidiary of Ono Pharmaceutical in 2024.
| Legal Name | Deciphera Pharmaceuticals, Inc. |
|---|---|
| Company Operating Status | Acquired |
| Crunchbase URL | https://www.crunchbase.com/organization/deciphera-pharmaceuticals |
| Email format | {f}{last} |
| Fax Number | 785.830.2150 |
| Full Address | 29-31 Rue de Courcelles 75008 Paris, France |
| LinkedIn URL | https://www.linkedin.com/company/deciphera-pharmaceuticals/ |
| Pitchbook URL | https://pitchbook.com/profiles/company/64797-94 |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.